Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors
- 1CIMR, Medical Genetics, Wellcome Trust/MRC Building, Addenbrooke’s Hospital, Cambridge, UK
- 2Summit plc, Abingdon, Oxfordshire, UK
- 3Department of Medicine, University of Cambridge, Cambridge, UK
- Dr D C Rubinsztein, CIMR, Medical Genetics, Wellcome Trust/MRC Building, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK; dcr1000{at}cam.ac.uk
- Received 19 January 2009
- Revised 6 March 2009
- Accepted 11 March 2009
- Published Online First 17 May 2009
Abstract
Background: Huntington’s disease is caused by expansion of a polyglutamine tract found in the amino-terminal of the ubiquitously expressed protein huntingtin. Well studied in its mutant form, huntingtin has a wide variety of normal functions, loss of which may also contribute to disease progression. Widespread transcriptional dysfunction occurs in brains of Huntington’s disease patients and in transgenic mouse and cell models of Huntington’s disease.
Methods: To identify new transcriptional pathways altered by the normal and/or abnormal function of huntingtin, we probed several nuclear receptors, normally expressed in the brain, for binding to huntingtin in its mutant and wild-type forms.
Results: Wild-type huntingtin could bind to a number of nuclear receptors; LXRα, PPARγ, VDR and TRα1. Over-expression of huntingtin activated, while knockout of huntingtin decreased, LXR mediated transcription of a reporter gene. Loss of huntingtin also decreased expression of the LXR target gene, ABCA1. In vivo, huntingtin deficient zebrafish had a severe phenotype and reduced expression of LXR regulated genes. An LXR agonist was able to partially rescue the phenotype and the expression of LXR target genes in huntingtin deficient zebrafish during early development.
Conclusion: Our data suggest a novel function for wild-type huntingtin as a co-factor of LXR. However, this activity is lost by mutant huntingtin that only interacts weakly with LXR.
Footnotes
-
Additional figures are published online only at http://jmg.bmj.com/content/vol46/issue7
-
Funding: This work is supported by the Wellcome trust, SiennaBiotech, MRC and DTI.
-
Competing interests: HD is an employee of Summit plc and has share options in this company.









